Published in Cardiovascular Week, January 17th, 2005
Researchers at the University of Alberta have discovered that a basic cellular process the body uses to balance pH in cells - also critical to recovery following a heart attack - is compromised by certain novel COX-2 inhibitors.
Bicarbonate transporters, enzymes critical to maintaining this delicate balance of bicarbonate across the cell membrane, are potently inhibited from doing their work by some clinically used nonsteroidal anti-inflammatory drugs such as celecoxib, the active ingredient in Celebrex.
Celecoxib is an...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.